Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

32.75
+0.35001.08%
Post-market: 32.750.00000.00%19:49 EST
Volume:556.52K
Turnover:18.19M
Market Cap:955.93M
PE:-75.43
High:33.31
Open:32.99
Low:31.64
Close:32.40
52wk High:44.28
52wk Low:14.59
Shares:29.19M
Float Shares:26.72M
Volume Ratio:1.10
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4342
EPS(LYR):0.6200
ROE:-2.69%
ROA:-1.72%
PB:2.05
PE(LYR):52.82

Loading ...

Castle Biosciences CEO Derek Maetzold Reports Disposal of Common Shares

Reuters
·
Yesterday

Castle Biosciences Inc. to Release Fourth Quarter and Full-Year Financial Results and Host Conference Call

Reuters
·
Feb 05

Castle Biosciences price target raised to $50 from $36 at KeyBanc

TIPRANKS
·
Jan 30

Castle Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 27

SciBase Holding AB Secures 82.7% Subscription in SEK 83 Million Rights Issue

Reuters
·
Jan 22

Castle Biosciences Is Maintained at Buy by Lake Street

Dow Jones
·
Jan 12

Castle Biosciences Expects 2025 Revenue to Exceed $340 Million

Reuters
·
Jan 12

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

THOMSON REUTERS
·
Jan 12

Castle Biosciences Inc - 2025 Total Revenue Expected to Exceed $340 Mln, Above Previously Guided Range of $327-335 Mln

THOMSON REUTERS
·
Jan 12

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Jan 08

Castle Biosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 06

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 30, 2025

Assessing Castle Biosciences (CSTL) Valuation After New Uveal Melanoma Data and Renewed Analyst Optimism

Simply Wall St.
·
Dec 25, 2025

Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests

Simply Wall St.
·
Dec 24, 2025

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 22, 2025

Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Dec 19, 2025

Castle Biosciences Grants RSUs to 83 New Employees under Inducement Plan

Reuters
·
Dec 19, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 19, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 18, 2025